Provectus Biopharmaceuticals annual revenue
2011
2012
2013
2014
2015
2022
2023
2024
2025
Provectus Biopharmaceuticals Revenue Growth & History (PVCT)
Provectus Biopharmaceuticals reported $336,108 in revenue for fiscal 2025, a decrease of 45.54% from the previous fiscal year.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $336,108 | −$281,032 | −45.54% |
| 2024 | 2024-12-31 | $617,140 | $59,430 | +10.66% |
| 2023 | 2023-12-31 | $557,710 | −$431,332 | −43.61% |
| 2022 | 2022-12-31 | $989,042 | — | — |
| 2015 | 2015-12-31 | $0 | $0 | — |
| 2014 | 2014-12-31 | $0 | $0 | — |
| 2013 | 2013-12-31 | $0 | $0 | — |
| 2012 | 2012-12-31 | $0 | $0 | — |
| 2011 | 2011-12-31 | $0 | — | — |
Provectus Biopharmaceuticals quarterly revenue
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $0 | −$278,628 | −100.00% |
| Q4 2025 | 2025-12-31 | $0 | −$14,332 | −100.00% |
| Q3 2025 | 2025-09-30 | $0 | −$109,745 | −100.00% |
| Q2 2025 | 2025-06-30 | $57,480 | −$197,511 | −77.46% |
| Q1 2025 | 2025-03-31 | $278,628 | $40,556 | +17.04% |
| Q4 2024 | 2024-12-31 | $14,332 | −$106,778 | −88.17% |
| Q3 2024 | 2024-09-30 | $109,745 | $40,012 | +57.38% |
| Q2 2024 | 2024-06-30 | $254,991 | $93,149 | +57.56% |
| Q1 2024 | 2024-03-31 | $238,072 | $33,047 | +16.12% |
| Q4 2023 | 2023-12-31 | $121,110 | −$43,727 | −26.53% |
| Q3 2023 | 2023-09-30 | $69,733 | −$245,157 | −77.85% |
| Q2 2023 | 2023-06-30 | $161,842 | −$159,868 | −49.69% |
| Q1 2023 | 2023-03-31 | $205,025 | $17,420 | +9.29% |
| Q4 2022 | 2022-12-31 | $164,837 | — | — |
| Q3 2022 | 2022-09-30 | $314,890 | — | — |
| Q2 2022 | 2022-06-30 | $321,710 | — | — |
| Q1 2022 | 2022-03-31 | $187,605 | — | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $0 | $0 | — |
| Q1 2016 | 2016-03-31 | $0 | $0 | — |
| Q4 2015 | 2015-12-31 | $0 | — | — |
| Q3 2015 | 2015-09-30 | $0 | — | — |
| Q2 2015 | 2015-06-30 | $0 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Provectus Biopharmaceuticals revenue growth trends
Provectus Biopharmaceuticals's latest reported quarter, Q1 2026, generated $0 in revenue, a decrease of 100.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Provectus Biopharmaceuticals source filings ↗